Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021.
COVID-19
ELISA
SARS-CoV-2
serology
seroprevalence
Journal
mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533
Informations de publication
Date de publication:
25 08 2021
25 08 2021
Historique:
pubmed:
5
8
2021
medline:
18
9
2021
entrez:
4
8
2021
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity was assessed for 3,066 individuals visiting hospitals in St. Louis, Missouri, during July 2020, November 2020, or January 2021. Seropositivity in children increased from 5.22% in July to 21.16% in January. In the same time frame, seropositivity among adults increased from 4.52% to 19.03%, prior to initiation of mass vaccination.
Identifiants
pubmed: 34346705
doi: 10.1128/mSphere.00450-21
pmc: PMC8386375
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0045021Subventions
Organisme : NIAID NIH HHS
ID : 75N93019C00062
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI151810
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007200
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201700060C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI132745
Pays : United States
Références
mSphere. 2021 Feb 3;6(1):
pubmed: 33536325
Bioinformatics. 2010 Jun 1;26(11):1403-8
pubmed: 20388627
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Immunity. 2020 May 19;52(5):737-741
pubmed: 32433946
Science. 2020 Jun 5;368(6495):1060-1061
pubmed: 32414781
Nat Commun. 2021 Mar 22;12(1):1813
pubmed: 33753738